AR121596A1 - Formas cristalinas de un agonista del receptor farnesoide x - Google Patents

Formas cristalinas de un agonista del receptor farnesoide x

Info

Publication number
AR121596A1
AR121596A1 ARP210100667A ARP210100667A AR121596A1 AR 121596 A1 AR121596 A1 AR 121596A1 AR P210100667 A ARP210100667 A AR P210100667A AR P210100667 A ARP210100667 A AR P210100667A AR 121596 A1 AR121596 A1 AR 121596A1
Authority
AR
Argentina
Prior art keywords
farnesoid
receptor agonist
crystalline forms
hydroxyazetidine
octan
Prior art date
Application number
ARP210100667A
Other languages
English (en)
Inventor
Nicholas D Smith
Robert Mansfield
Original Assignee
Metacrine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metacrine Inc filed Critical Metacrine Inc
Publication of AR121596A1 publication Critical patent/AR121596A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Una forma cristalina de 3-hidroxiazetidina-trans-1-carboxilato de 4-((4-(1-(tert-butil)-1H-pirazol-4-il)piridin-2-il)((4-(4-metoxi-3-metilfenil)biciclo[2.2.2]octan-1-il)metil)carbamoil)ciclohexilo, o una sal o solvato farmacéuticamente aceptables de este. Reivindicación 2: La forma cristalina de la reivindicación 1, caracterizada por que la 3-hidroxiazetidina-trans-1-carboxilato de 4-((4-(1-(tert-butil)-1H-pirazol-4-il)piridin-2-il)((4-(4-metoxi-3-metilfenil)biciclo[2.2.2]octan-1-il)metil)carbamoil)ciclohexilo es de base libre.
ARP210100667A 2020-03-18 2021-03-17 Formas cristalinas de un agonista del receptor farnesoide x AR121596A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062991213P 2020-03-18 2020-03-18

Publications (1)

Publication Number Publication Date
AR121596A1 true AR121596A1 (es) 2022-06-22

Family

ID=77771306

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100667A AR121596A1 (es) 2020-03-18 2021-03-17 Formas cristalinas de un agonista del receptor farnesoide x

Country Status (13)

Country Link
US (1) US20230147756A1 (es)
EP (1) EP4121010A4 (es)
JP (1) JP2023518399A (es)
KR (1) KR20220155356A (es)
CN (1) CN115666521A (es)
AR (1) AR121596A1 (es)
AU (1) AU2021236648A1 (es)
BR (1) BR112022018596A2 (es)
CA (1) CA3171987A1 (es)
IL (1) IL296532A (es)
MX (1) MX2022011582A (es)
TW (1) TW202144332A (es)
WO (1) WO2021188692A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021004919A2 (pt) 2018-09-18 2021-06-01 Metacrine, Inc. agonistas de receptor farnesoide x e usos dos mesmos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
JP7174709B2 (ja) * 2017-03-15 2022-11-17 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
JP7258763B2 (ja) * 2017-03-15 2023-04-17 メタクリン，インク． ファルネソイドｘ受容体アゴニストおよびその使用
BR112021004919A2 (pt) * 2018-09-18 2021-06-01 Metacrine, Inc. agonistas de receptor farnesoide x e usos dos mesmos
EP3852736A4 (en) * 2018-09-18 2022-05-18 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF

Also Published As

Publication number Publication date
US20230147756A1 (en) 2023-05-11
BR112022018596A2 (pt) 2023-03-07
KR20220155356A (ko) 2022-11-22
EP4121010A1 (en) 2023-01-25
AU2021236648A1 (en) 2022-10-13
JP2023518399A (ja) 2023-05-01
MX2022011582A (es) 2022-12-13
IL296532A (en) 2022-11-01
CN115666521A (zh) 2023-01-31
TW202144332A (zh) 2021-12-01
WO2021188692A1 (en) 2021-09-23
CA3171987A1 (en) 2021-09-23
EP4121010A4 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
CR20190343A (es) FORMAS DE DOSIFICACIÓN DE LIBERACIÓN PROLONGADA PARA UN INHIBIDOR DE JAK 1 (Divisional de Exp: 2016-0102)
AR078411A1 (es) Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende
CO2019005045A2 (es) Formas cristalinas de un inhibidor de magl.
AR121596A1 (es) Formas cristalinas de un agonista del receptor farnesoide x
CL2021002651A1 (es) Métodos de tratamiento del linfoma no hodgkin usando 2- (2,6-dioxopiperidin-3-yl) -4 - ((2-fluoro-4 - ((3-morfolinoazetidin-1-yl) metil) bencil) amino) isoindolina- 1,3-diona
PE20121820A1 (es) (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2-carboxamida, formas de sales novedosas de ella, y metodos de uso de ella
AR117573A1 (es) Formas cristalinas de un inhibidor tlr7 / tlr8
BRPI0512958A (pt) antagonistas de nk1
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CR8931A (es) Benzoxazoles sustituidos con profarmaco como agentes estrogenicos
TWD214327S (zh) 氣溶膠產生裝置
CO2022018446A2 (es) Compuestos de piperidina sustituida y su uso
AR107963A1 (es) Forma cristalina de sales de 1-(5-(2,4-difluorfenil) -1-((3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina
DOP2011000093A (es) Inhibidores de la integrasa del vih
AR099982A2 (es) Uso de (r)-3-[1-(2,6-dicloro-3-fluoro-fenil)-etoxi]-5-(1-piperidin-4-il-1h-pirazol-4-il)-piridin-2-ilamina o una sal farmacéuticamente aceptable del mismo para la preparación de un medicamento
CO2022005861A2 (es) Terapia de combinación con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
DOP2022000099A (es) Antagonistas heterocíclicos de nmda
AR041455A1 (es) Combinacion de un inhibidor del factor xa y clopidogrel
CO5611134A2 (es) Composiciones farmaceuticas que contienen sales de tiotropio y nuevos agentes inhibidores de la cinasa egfr
DK1471916T3 (da) Behandling af rheumatoid arthritis under anvendelse af imatinib
AU2003216621A8 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
JP1715876S (ja) 家具用構成材
JP1721787S (ja) テーブル
TWD206552S (zh) 用於鑽孔機之固持器之把手部分
AR127545A1 (es) Formas cristalinas de un inhibidor de la monoacilglicerol lipasa